Introduction
Induced sputum analysis has become an important direct, non-invasive method for the assessment of airway inflammation.
Since the first description of a standardised method [1] there has been an impressive increase of papers in which researchers have used induced sputum to study various aspects of airway inflammation. In order to harmonise the different techniques used worldwide a standardised methodology of sputum induction and processing was issued in 2002 by a European Respiratory Society Task Force [2] .
Several studies have shown that evaluation of induced sputum cells is a reproducible and valid technique [3] [4] [5] . In particular, one study evaluated the reproducibility of cell counts on cytospins and fluid phase measurements in selected portion of induced sputum. A high reproducibility within sample, between sample and between examiners for all types of cells was reported [3] . Moreover, measurements between different airway diseases were successfully detected, thus confirming the validity of the technique [3] .
Reference values and the distribution of cell counts in induced sputum have been provided in a large number of healthy volunteers [6, 7] . The induced sputum was found rich in macrophages and neutrophils and poor in eosinophils, lymphocytes and epithelial cells. These parameters can be used in comparisons with induced sputum cell counts of subjects with airway inflammation [6] .
Furthermore, sputum induction has been found to be a simple, safe and well tolerated procedure even in patients with severe lung disease and having exacerbations. However, it has been recommended that experienced personnel carry out the operation and that they apply standard operating procedures, to be aware of the degree of airway obstruction, to use a modified protocol for subjects with severe airway obstruction and to assess lung function and symptoms during sputum induction procedure [8] .
Over the last 15 years sputum analysis has become one of the most referenced methods to assess airway inflammation in research and clinical practice [9] . In particular, it has been useful in the characterisation of the type and the extent of airway inflammation in asthma, Chronic Obstructive Pulmonary Disease (COPD) and chronic cough, and During recent years there has been a growing interest in using non-invasive biomarkers to understand and monitor the airway inflammation in subjects with respiratory tract disorders.
To date, the best validated and performing non-invasive biomarkers are measures of inflammation in induced sputum in both cellular and fluid phase, which can provide biological insights into the pathogenesis of respiratory diseases such as asthma and chronic obstructive pulmonary disease.
The as lung cancer, cystic fibrosis and interstitial lung diseases.
The aim of the present paper was to review the principal literature on the different markers of inflammation in pulmonary diseases assessed by induced sputum analysis in both cellular and fluid phase.
Asthma
Since the first study in 1992 [1] many authors have validated the measurements of both cellular and soluble components related to asthma.
These studies have significant in the comprehension of the inflammatory processes that play a role in the development and maintenance of the disease.
Therefore there has recently been a growing interest in the application of induced sputum for monitoring and optimisation of asthma control.
Cellular composition
Sputum eosinophilia is a typical feature of asthma. Sputum eosinophil count is a validated biomarker for the assessment of airway inflammation that can be easily performed even in clinical setting. Asthmatic patients with sputum eosinophilia have a positive response to corticosteroids, even in ex-smokers and current smokers [10] .
Increased sputum eosinophils are associated to a thickening of the greater basement membrane [11] . Some authors have recently suggested that sputum eosinophilia may reflect inadequate control airway inflammation, resulting in an increased risk of exacerbation [12] [13] [14] .
Conversely, a considerable percentage of corticosteroid-free asthmatics (ranging from 25 to 55%) show a neutrophilic inflammation [15] [16] [17] . This condition is called non-eosinophilic asthma and it is important to identify because it is associated with a poor response to corticosteroids [16] .
Fluid-phase mediators
Although the validity and reproducibility of several techniques has not been assessed yet, many potential biomarkers can be examined in induced sputum supernatant (table 1) . 
↑ Eosinophils (likely overlap with asthma. ↑ Neutrophils Better response to corticosteroids)
Eosinophil Cationic Protein (ECP) and Myeloperoxidase (MPO) are granulocyte proteins that are well correlated with eosinophil cell count [18] and decrease after anti-nflammatory treatment [19, 20] .
Levels of leakage markers such as albumin and fibrinogen were found increased in subjects with asthma compared to healthy subjects [4] and their concentrations are related to asthma severity [21, 22] .
Moreover, recent studies showed that asthmatic subjects have increased concentrations of nonkinase plasminogen activator and plasminogen activator inhibitor [23] compared to controls and Neurokinin A significantly raises during exacerbations [24] . Interleukin-8 (IL-8) is a neutrophil chemoattractant which has been shown to be increased during asthma exacerbations [25] and in patients with severe persistent asthma [17] , suggesting a role for monitoring asthma exacerbations and assessing the effectiveness of a medication in severe asthmatics. IL-13 is another cytokine whose levels were found higher in asthmatics than controls [26] . However it occurred in less than 50% of asthmatics and no correlation with asthma severity was found [26] .
Cysteinyl leukotrienes (Cys-LTs) and 8-isoprostane are inflammatory mediators involved in the pathophysiology of asthma [27, 28] . Both have been extensively studied during recent years [29, 30] and their concentration correlates with severity of disease and are relatively unaffected by corticosteroids [31] [32] [33] . However 8-isoprostane was not found to be increased in newly diagnosed subjects with asthma [34] . Finally, asthmatic subjects show a higher level of Matrix metalloproteinasis-9 (MMP-9) [35] [36] [37] [38] [39] . In the process of remodelling an impairment in the balance between MMP-9 and its counterpart tissue inhibitor of metalloproteinases (TIMP) occurs. Indeed, asthmatic subjects have an increase in MMP-9/TIMP ratio that is related to the disease severity [35, 36, 40] .
Chronic obstructive pulmonary disease
Induced sputum has been broadly used to investigate the inflammatory mechanism of COPD and it has provided considerable information about the inflammatory process of this disease. Although patients with COPD expectorate spontaneously it is suggested to perform induced sputum, since spontaneous sputum may contain a high amount of dead cells [4] that may lead to errors during cell count and fluid-phase mediators measurements [41, 42] .
Cellular composition
An increase in the percentage of neutrophils is the typical feature in subjects with COPD [43] [44] [45] . Neutrophils are increased compared to asymptomatic smokers and there is a negative correlation between neutrophil counts and FEV 1 [46] . This indicates that neutrophils are relevant in the pathogenesis of COPD.
Some COPD patients show an increased number of eosinophils, indicating a likely overlap with asthma, and this seems to predict a better response to bronchodilators and inhaled corticosteroids [47] .
Moreover, CD8+ T-cells are increased in induced sputum of patients with COPD [48] . It has been shown that the CD8+ T-cells involved in COPD are type 1 [49] . Type 1 cells play a role in the response to viral infections that are frequent in patients with COPD [50] .
Inflammatory mediators
Many inflammatory mediators have been analysed in the fluid-phase of induced sputum (table 1) . Several cytokines, chemokines, eicosanoids, markers of oxidative stress show an increase in COPD compared to asymptomatic smokers, with a further increase during exacerbations. In particular, inflammatory cytokines, including Interleukin-8 (IL-8), Interleukin 6 (IL-6) and Tumour Necrosis Factor-alpha (TNF-α) have been extensively studied and reported increased in sputum of COPD patients compared to normal smokers [51] [52] [53] [54] and their concentrations are related to the severity of the disease [55] . However the inflammatory cytokine Interleukin-10 (IL-10) are reduced in sputum of healthy smokers and, to a greater extent, in smokers with COPD [56] , suggesting a role of the imbalance between cytokines with different properties in the smoke-induced lung damage.
Induced sputum of patients with COPD shows an increase of Leptin that is correlated with other inflammatory markers including TNF-α and C-reactive protein (CRP) [57] .
Moreover, sputum fluid-phase in COPD shows an increase in neutrophilic and eosinophilic granulocyte proteins such as Myeloperoxidase (MPO), Human Neutrophil Lipocalin (HNL), Neutrophil Elastase (NE) and Eosinophilic Cationic Protein (ECP), Eosinophil Peoxidase (EPO) and chemoattractants like Leukotriene B-4 (LTB-4), Growth Related Oncogen-a (GRO-a), Monocyte Chemotactic Protein-1 (MCP-1) and Granulocyte Macrophages-Colony Stimulating Factor (GM-CSF) [58] [59] [60] .
Increased sputum concentration of proteins, including neutrophil Elastase and Metallopro- [59, [61] [62] [63] .
Finally, higher levels of Hyaluronan indicate a leakage in the extracellular matrix in COPD [64] .
Cystic fibrosis
Cystic fibrosis is the most common lethal genetically inherited disease characterised by a self perpetuating cycle of airway obstruction, chronic bacterial infection, and vigorous inflammation that results in bronchiectasis, progressive obstructive lung disease, and marked shortening of life expectancy [65] . Airway inflammation plays an important role in the progression of cystic fibrosis. Thus, inflammatory biomarkers in sputum of patients with cystic fibrosis can be utilised for monitoring disease progression and evaluation of treatment.
Airway inflammation in cystic fibrosis is characterised by the presence of abundant amounts of neutrophils, neutrophil products, as well as epithelial cells, macrofages, T lymphocytes, B lymphocytes, dendritic cells and mast cells [66] . Sputum has been used extensively to evaluate airway inflammation in cystic fibrosis. Various markers including inflammatory cells, cytokines, cytokine antagonists, neutrophil chemoattractants, proteases, antiproteases, markers of oxidative stress, antioxidants, plasma exudates markers, antimicrobial proteins, antimicrobial peptides, nitric oxide metabolites and pathway, eicosanoids, mucins, adhesion molecules, markers of structural airway injury and components of signaling cascades that can be measured in sputum were suggested [66] . The most important indicators of airway inflammation in sputum of patients with cystic fibrosis are the increase of total cell counts, as well as neutrophil counts and increased level of interleukin-8 [67] . Inflammatory markers can be studied in spontaneously produced and induced sputum. Administration of sputum induction is a good solution to evaluate airway inflammation in patients who are not able to produce sputum spontaneously. Total cell counts, as well as neutrophil counts in induced sputum are significantly increased in comparison with sputum obtained from healthy individuals [68] . However, the degree of this inflammation is not significantly different from those evaluated in patients with cystic fibrosis who have a productive cough and can produce sputum spontaneously [68] . Similarly, IL-8 levels and neutrophil elastase activity are similar in spontaneously produced and induced sputum [68] . This indicates that the analysis of induced and/or spontaneously produced sputum can provide relevant useful information for evaluation and monitoring of patients with cystic fibrosis. However, other studies are required to further investigate relationship between variability of inflammatory biomarkers and disease severity.
Lung cancer
Lung cancer has an important clinical and socio-economical significance, as it is the most common and the most lethal cancer in many countries of the world. Several studies have documented the possibility of diagnosing lung cancer by using sputum cytology [69] [70] [71] . A method based on identification of biomarkers of lung cancer in the sputum of suspects can be performed for early diagnosis of this pathology. This can be very useful especially in patients affected by early stage of lung cancer when traditional methods of diagnosis are not yet able to reveal the disease. For example, sputum cytology is useful in finding early central lung cancer, particularly squamous cell carcinoma in situ and microinvasive squamous cell carcinoma [70] . However, most of the studies demonstrated that sputum cytology had low sensitivity in discovering clinical lung cancer [71] . The poor sensitivity of sputum cytology can be explained by an inadequate sample of sputum collected for cytological examination. Induction of sputum in subjects who are not able to produce sputum spontaneously or who produce inadequate samples of sputum may solve the problem. In addition, sputum induction may presumably provide more robust samples and increase sensitivity of cytological examination in subjects who produce samples of sputum suitable for analysis. Advances in improved yield of expectoration and improved methods of evaluating sputum are crucial points for future investigations.
Sarcoidosis
Sarcoidosis is a systemic granulomatous disease characterised by a T-helper-1 response with accumulation of CD4+ lymphocytes and activated macrophages in the lungs and affected organs, resulting in granuloma formation [72] . The immune response in the pathogenesis of sarcoidosis is mediated by alveolar macrophages and lymphocytes making these two cells biomarkers of the disease. Some studies have demonstrated that sputum of a patients with sarcoidosis is characterised by relatively high lymphocyte counts [73] . However, the evidence of other biomarkers is missing. Identification of mediators secreted by lymphocyte in sputum of patients with sarcoidosis is the objective for future research. 
Conclusions
As seen above induced sputum is a validated technique that can be applied in several pulmonary diseases both for research and diagnosis and it has potentials for a large-scale application in several clinical settings.
It is important to consider the most relevant advantages and disadvantages of the discussed technique. Induced sputum has several pro's including reproducibility of differential cell count on cytospins, the possibility to sample multiple biomarkers, its validity as a tool for assessment of anti-inflammatory therapy and its relative non-invasiveness.
However a number of cons have to be taken into account. Sputum induction and processing are expensive and time-consuming procedures that require well-equipped laboratories with trained personnel and rescue medication promptly available.
Moreover, adequate samples cannot be obtained from all the subjects (80% on average) and sputum induction should not be performed in patients with severe persistent bronchocostiction and/or co-morbidities such as cardiovascular disorders.
Induced sputum should not be repeated over a short-term period (< 48/h) as it may affect the composition of inflammatory cells and mediators in the airways [74, 75] .
Finally, the processing of sputum with dithiotreitol may affect the measurement of fluidphase mediators for its action on disulphide bonds [76] [77] [78] and the lack of a validated dilution factor may lead to incomparable measurements among authors.
